Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The GLOW Protocol typically features a compounded peptide formulation containing: GHK-Cu 10 mg BPC-157 3 mg TB-500 3.75 mg per mL This protocol is typically used as part of a 30-day regimen , though treatment recommendations may vary depending on the patient, goals, and provider guidance
Is BPC 157 banned in Australia or is it legal
Because retatrutide is not a licensed medicine and has no approved SmPC, any reconstitution volumes described below are strictly illustrative of general peptide reconstitution principles and must not be interpreted as clinical dosing advice or as an endorsement of human use outside of a formal clinical trial
Follow-up Re-check metabolic markers and IGF-1 after 6-8 weeks, with earlier review if GI symptoms, glucose symptoms, or fluid retention occur
How it works: GHRH receptor binding: Sermorelin binds pituitary somatotroph GHRH receptors, activating adenylyl cyclase and increasing intracellular cAMP to trigger synthesis and pulsatile release of endogenous GH IGF-1 upregulation: elevated GH drives hepatic IGF-1 production, which mediates the downstream anabolic effects including lean mass accretion, bone density support, and tissue remodeling Preserved feedback regulation: because sermorelin works through the hypothalamic-pituitary axis rather than bypassing it, natural somatostatin-mediated negative feedback remains intact, reducing the risk of GH excess seen with exogenous HGH Extracellular matrix support: preclinical models suggest GH axis stimulation may reduce inflammatory cytokine signaling and promote extracellular matrix remodeling, contributing to faster soft tissue recovery Administration: Subcutaneous injection (intramuscular also used) Typical dosing range: 200-500 mcg once daily, most protocols use 300 mcg nightly
